KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

CRISPR Therapeutics AG (CRSP) Tax Provisions (2016 - 2025)

Historic Tax Provisions for CRISPR Therapeutics AG (CRSP) over the last 11 years, with Q4 2025 value amounting to $614000.0.

  • CRISPR Therapeutics AG's Tax Provisions fell 4756.62% to $614000.0 in Q4 2025 from the same period last year, while for Dec 2025 it was $3.6 million, marking a year-over-year decrease of 1106.23%. This contributed to the annual value of $3.6 million for FY2025, which is 1073.45% down from last year.
  • Latest data reveals that CRISPR Therapeutics AG reported Tax Provisions of $614000.0 as of Q4 2025, which was down 4756.62% from $619000.0 recorded in Q3 2025.
  • In the past 5 years, CRISPR Therapeutics AG's Tax Provisions ranged from a high of $6.1 million in Q2 2022 and a low of -$8.5 million during Q4 2022
  • Moreover, its 5-year median value for Tax Provisions was $812000.0 (2024), whereas its average is $675250.0.
  • Data for CRISPR Therapeutics AG's Tax Provisions shows a peak YoY increase of 93575.0% (in 2021) and a maximum YoY decrease of 107958.12% (in 2021) over the last 5 years.
  • CRISPR Therapeutics AG's Tax Provisions (Quarter) stood at -$2.3 million in 2021, then crashed by 277.94% to -$8.5 million in 2022, then surged by 107.19% to $612000.0 in 2023, then surged by 91.34% to $1.2 million in 2024, then tumbled by 47.57% to $614000.0 in 2025.
  • Its last three reported values are $614000.0 in Q4 2025, $619000.0 for Q3 2025, and $1.3 million during Q2 2025.